3 recruiting, 2 unknown, 1 completed, 1 not yet recruiting. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Unknown 2, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Extrahepatic Cholangiocarcinoma: new trials by email Literature Review of Extrahepatic Cholangiocarcinoma trials Research Report on Extrahepatic Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-08-28 |
| Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma Pembrolizumab, Gemcitabine, Cisplatin - Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma | Phase 2 / Phase 3 | Recruiting | Amsterdam UMC, location VUmc | 150 | 2026-04-17 | 2026-08-25 |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma Gemcitabine, Cisplatin, Durvalumab - Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 42 | 2024-08-23 | 2026-10-23 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma Toripalimab, Gemcitabine,Oxaliplatin - Extrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Xuhua Duan | 45 | 2022-06-15 | 2022-07-07 |
| Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Irinotecan Liposome Injection, SG001, Fluorouracil - Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 | Terminated | CSPC Ouyi Pharmaceutical Co., Ltd. | 17 | 2021-09-01 | 2024-07-11 |
| Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer Chemotherapy, Observation, Immunotherapy - Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Sun Yat-sen University | 92 | 2020-06-01 | 2020-06-23 |
Cholangiocarcinoma (8) · Gallbladder Neoplasms (5) · Biliary Tract Neoplasms (3) · Bile Duct Neoplasms (1) · Carcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Disease Progression (1) · Gastrointestinal Neoplasms (1) · Klatskin Tumor (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1)
Adenocarcinoma (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (8) · Carcinoma (7) · Biliary Tract Diseases (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gallbladder Diseases (5) · Neoplasms by Site (5) · Biliary Tract Neoplasms (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bile Duct Diseases (1) · Disease Attributes (1)
Gemcitabine (4) · Cisplatin (3) · Fluorouracil (2) · Leucovorin (2) · Oxaliplatin (2) · durvalumab (2) · Cyclophosphamide (1) · Drug Therapy (1) · Folfox protocol (1) · Immunotherapy (1) · Observation (1) · Radiotherapy (1) · fludarabine (1) · irinotecan sucrosofate (1) · pembrolizumab (1)
Amsterdam UMC, location VUmc (1) · Beijing Biotech (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Lisata Therapeutics, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Sun Yat-sen University (1) · Xuhua Duan (1)
China (4) · United States (2) · Germany (1) · Netherlands (1)
Kristen K Buck, MD (1) · Ming Kuang, PhD (1) · Nilo Azad, MD (1) · Salah-Eddin SE Al-Batran, Prof. Dr. (1) · Xiangdong Cheng (1)
2023 (2)